(Q38991698)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24859811%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

title

Anti-L1CAM radioimmunotherapy is more effective with the radiolanthanide terbium-161 compared to lutetium-177 in an ovarian cancer model (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24859811%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

1 reference

0 references

1 reference

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24859811%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

Eliane Fischer

series ordinal

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24859811%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

6

Ulli Köster

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24859811%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

7

Andreas Türler

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24859811%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

Konstantin Zhernosekov

series ordinal

5

object named as

Konstantin Zhernosekov

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24859811%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

3

Holger Dorrer

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24859811%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

1

Jürgen Grünberg

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24859811%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

4

Susan Cohrs

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24859811%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

author name string

Dennis Lindenblatt

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24859811%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

publication date

24 May 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24859811%20AND%20SRC:MED&resulttype=core&format=json

European Journal of Nuclear Medicine and Molecular Imaging

19 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24859811%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

volume

41

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24859811%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

issue

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24859811%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

page(s)

1907-1915

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24859811%20AND%20SRC:MED&resulttype=core&format=json

Beyond chemotherapy: targeted therapies in ovarian cancer

19 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2798-3

The management of recurrent ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2798-3

Profile of erlotinib and its potential in the treatment of advanced ovarian carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2798-3

Phase II evaluation of imatinib mesylate in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2798-3

L1 cell adhesion molecule (L1CAM) in invasive tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2798-3

L1CAM: a major driver for tumor cell invasion and motility

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2798-3

The L1 cell adhesion molecule as a target for radioimmunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2798-3

L1 expression as a marker for poor prognosis, tumor progression, and short survival in patients with colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2798-3

L1 expression as a predictor of progression and survival in patients with uterine and ovarian carcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2798-3

Expression profile analysis in multiple human tumors identifies L1 (CD171) as a molecular marker for differential diagnosis and targeted therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2798-3

Copper-67 radioimmunotherapy and growth inhibition by anti-L1-cell adhesion molecule monoclonal antibodies in a therapy model of ovarian cancer metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2798-3

Therapeutic antibodies to human L1CAM: functional characterization and application in a mouse model for ovarian carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2798-3

The soluble form of the cancer-associated L1 cell adhesion molecule is a pro-angiogenic factor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2798-3

Internalization and degradation of monoclonal antibody chCE7 by human neuroblastoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2798-3

In vivo evaluation of 177Lu- and 67/64Cu-labeled recombinant fragments of antibody chCE7 for radioimmunotherapy and PET imaging of L1-CAM-positive tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2798-3

Determination of the immunoreactive function of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2798-3

Revised effective ionic radii and systematic studies of interatomic distances in halides and chalcogenides

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2798-3

A rare earth-DOTA-binding antibody: probe properties and binding affinity across the lanthanide series

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2798-3

Rapid elimination of mouse/human chimeric monoclonal antibodies in nude mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2798-3

The amazing world of auger electrons

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2798-3

Cell membrane is a more sensitive target than cytoplasm to dense ionization produced by auger electrons.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2798-3

Apoptosis and p53 are not involved in the anti-tumor efficacy of ¹²⁵I-labeled monoclonal antibodies targeting the cell membrane.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2798-3

Molecular and cellular radiobiological effects of Auger emitting radionuclides

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2798-3

Auger radiation targeted into DNA: a therapy perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2798-3

The role of p53 in combination radioimmunotherapy with 64Cu-DOTA-cetuximab and cisplatin in a mouse model of colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2798-3

111In-Labeled Trastuzumab (Herceptin) Modified with Nuclear Localization Sequences (NLS): An Auger Electron-Emitting Radiotherapeutic Agent for HER2/neu-Amplified Breast Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-014-2798-3

Nuclear localizing sequences promote nuclear translocation and enhance the radiotoxicity of the anti-CD33 monoclonal antibody HuM195 labeled with 111In in human myeloid leukemia cells

21 January 2018

1 reference

12 December 2020

Rapid blood clearance of mouse IgG2a and human IgG1 in many nude and nu/+ mouse strains is due to low IgG2a serum concentrations

1 reference

12 December 2020

Auger electrons: lethal, low energy, and coming soon to a tumor cell nucleus near you.

1 reference

12 December 2020

L1-CAM as a target for treatment of cancer with monoclonal antibodies

1 reference

12 December 2020

L1 is associated with micrometastatic spread and poor outcome in colorectal cancer

1 reference

12 December 2020

The low-energy β− and electron emitter 161Tb as an alternative to 177Lu for targeted radionuclide therapy

1 reference

12 December 2020

L1-CAM-targeted antibody therapy and 177Lu-radioimmunotherapy of disseminated ovarian cancer

1 reference

12 December 2020

L1-CAM in cancerous tissues

1 reference

12 December 2020

Radiation-induced biologic bystander effect elicited in vitro by targeted radiopharmaceuticals labeled with alpha-, beta-, and auger electron-emitting radionuclides.

1 reference

12 December 2020

Therapeutic advantages of Auger electron- over beta-emitting radiometals or radioiodine when conjugated to internalizing antibodies

1 reference

12 December 2020

Efficient inhibition of intra-peritoneal tumor growth and dissemination of human ovarian carcinoma cells in nude mice by anti-L1-cell adhesion molecule monoclonal antibody treatment

1 reference

12 December 2020

10.1007/S00259-014-2798-3

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24859811%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

1 reference